2026 NPPES data Hematology & Oncology Physician NPI 1639152986 MD
Verify on CMS →

MARK BOATRIGHT, MD

Hematology & Oncology Physician in PENSACOLA, Florida. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
162
Medicare Part D claims · 55 beneficiaries · Hematology & Oncology Physician avg: 847
Generic prescribing
91%
generic claims · 9% brand-name · higher generic rates reduce patient out-of-pocket costs
MIPS score
90.8442/100
▲ 8 pts above national avg 83.1 · [object Object]
What the federal data reveals: MARK BOATRIGHT, MD is a Hematology & Oncology Physician ([object Object]) practicing in PENSACOLA, Florida with a Medicare Part D prescribing footprint of 162 claims across 55 beneficiaries — 9% brand-name prescribing . Their CMS MIPS Final Score of 90.8442/100 (national average: 83.1) reflects performance across Quality, Cost, Interoperability, and Improvement Activities .

What stands out: MARK BOATRIGHT, MD reported a CMS MIPS final score of 90.8442 out of 100, above the 83.1 national average, and filed 162 Medicare Part D claims in 2023. Every figure on this page comes straight from federal CMS records, with no proprietary rating applied.

Board certification likely (heuristic — not verified)

MARK BOATRIGHT, MD practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).

MARK BOATRIGHT, MD at a glance

High performer (top quartile)

NPI registry status

Active

Issued 11/21/2005

NPI 1639152986

Primary specialty

Hematology & Oncology Physician

Mid-sized

11,215 US NPIs in this specialty

Medicare Part D claims

162 81% vs specialty avg

2023 prescription claims

Specialty avg: 847

MIPS final score

90.8442/100 7.744200000000006% pts

Exceptional band

vs 83.1 national avg

Specialty distribution in Florida

How Hematology & Oncology Physician compares to other specialties among Florida providers

Florida providers

Hematology & Oncology Physician share within Florida

1. Hematology & Oncology Physician42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Hematology & Oncology Physician share within Florida

Medicare quality performance — MIPS

MARK BOATRIGHT, MD's 2023 MIPS final score plotted against the Hematology & Oncology Physician national average

High performer (top quartile)
MIPS Final Score
90.8442/100
vs 83.1 national avg · 2023 performance year

MIPS final score (Hematology & Oncology Physician) — 90.8442/100 vs national avg 83.1

0%100%National avg83%90.8%
MIPS final score (Hematology & Oncology Physician) — 90.8442/100 vs national avg 83.1

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

MARK BOATRIGHT, MD is a Hematology & Oncology Physician provider practicing in PENSACOLA, Florida, according to the CMS National Plan and Provider Enumeration System (NPPES). Credentials: MD. NPI: 1639152986. This profile includes practice location, specialty classification, and organizational affiliations from the CMS provider registry. Provider information is self-reported to CMS and updated monthly.

MARK BOATRIGHT, MD appears in the CMS NPPES registry as a Hematology & Oncology Physician provider holding MD credentials at 1545 AIRPORT BLVD, PENSACOLA, FL, 32504, with a listed phone of (850) 416-6933. NPI 1639152986 was issued on 11/21/2005. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what BOATRIGHT most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 162 prescription claims written by this provider, covering 55 Medicare beneficiaries and totaling roughly $134K in drug spend, split 9% brand-name and 91% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 90.8442/100 for the 2023 performance year (Quality 81.6885), compared with the national average of 83.1.

Hematology & Oncology Physician is a mid-sized specialty nationwide, with 11,215 enrolled providers across 54 states and an average of 847 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

1545 AIRPORT BLVD
PENSACOLA, FL 32504

Provider Details

NPI 1639152986
Specialty Hematology & Oncology Physician
Credentials MD
Gender Male
NPI Issued 11/21/2005

CMS Quality Score (MIPS)

Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.

90.8442
Final Score
Avg: 83.1
81.6885
Quality
100
Promoting Interoperability

Reporting: Alternative Payment Model

License & disciplinary context — Florida FLDOH 2023 annual report

Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~75K Florida medical licensees in 2023 — they are NOT specific to MARK BOATRIGHT, MD. To verify MARK BOATRIGHT, MD's current license status, search the FLDOH public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.

480
Total board actions, Florida 2023
Across 467 cases
6.40
Actions per 1,000 licensees
Florida statewide rate
monetary fine
Most common action type
138 cases

FLDOH publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Florida disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.

Brand vs generic prescribing mix · Generic-heavy

MARK BOATRIGHT, MD — brand share 9.0%
Specialty average (est.)

9% brand-name claims vs 91% generic, on 162 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

162
Total Claims
$134K
Total Drug Cost
55
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
291
Total Day Supply
8,273
Brand vs Generic
9% brand / 91% generic
Brand Drug Cost
$112K
Generic Drug Cost
$23K

Patient Demographics

Average Patient Age
71.5 years
Avg HCC Risk Score
1.85
Gender Split
76% female / 24% male

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

Drug Claims
Anastrozole
38
Letrozole
14
Ondansetron Hcl
12

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Hematology & Oncology Physician Overview

How MARK BOATRIGHT, MD fits within the Hematology & Oncology Physician landscape nationally.

11,215
Hematology & Oncology Physician Providers in US
54
States with Hematology & Oncology Physician
847
Avg Claims per Provider

MARK BOATRIGHT, MD's 162 claims are below the specialty average of 847.

Nearby Hematology & Oncology Physician Providers in Florida

Other clinicians with the same primary specialty enrolled in Florida, drawn from the same CMS NPPES roster as BOATRIGHT.

Compare Hematology & Oncology Physician nationally: see state-by-state distribution →

Frequently Asked Questions

What is MARK BOATRIGHT, MD's specialty?
MARK BOATRIGHT, MD specializes in Hematology & Oncology Physician and practices in PENSACOLA, Florida. Credentials: MD.
How much does MARK BOATRIGHT, MD prescribe under Medicare Part D?
In 2023, MARK BOATRIGHT, MD wrote 162 Medicare Part D claims totaling $134K in drug costs for 55 beneficiaries.
What is MARK BOATRIGHT, MD's Medicare quality score?
MARK BOATRIGHT, MD has a CMS MIPS Final Score of 90.8442/100 (Quality: 81.6885). The national average MIPS Final Score is 83.1. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is MARK BOATRIGHT, MD located?
MARK BOATRIGHT, MD is located at 1545 AIRPORT BLVD, PENSACOLA, FL, 32504. Phone: (850) 416-6933.
What is MARK BOATRIGHT, MD's NPI number?
MARK BOATRIGHT, MD's National Provider Identifier (NPI) is 1639152986, issued on 11/21/2005.
Does MARK BOATRIGHT, MD prescribe more brand-name or generic drugs?
MARK BOATRIGHT, MD's prescribing is 9% brand-name and 91% generic drugs by claim count, with $112K in brand drug costs.
How many Hematology & Oncology Physician providers are there in the US?
There are 11,215 Hematology & Oncology Physician providers across 54 states in the US. The average Hematology & Oncology Physician provider writes 847 Medicare Part D claims per year.
What drugs does MARK BOATRIGHT, MD prescribe most often?
Based on 2023 Medicare Part D data, MARK BOATRIGHT, MD's most frequently prescribed drugs include Anastrozole, Letrozole, Ondansetron Hcl. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does MARK BOATRIGHT, MD accept Medicare?
MARK BOATRIGHT, MD appears in CMS Medicare data with 162 Part D claims and 55 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify MARK BOATRIGHT, MD's credentials?
MARK BOATRIGHT, MD's NPI is 1639152986 with credentials MD. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Quality Performance
CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology